Stressors are one of several environmental variables, which lead to mental illness. The adoption of sensitivity related with important biomarkers in the detection, assessment, and validation procedures is now necessary due to unmet medical outcomes and monitoring platforms in the field of mental diseases. By validating the functional efficacy of medications or the state of brain function recovery using behavioural assessment and metabolomics, which includes a neuro-pharmacogenomics study, the use of omics in mental disorders and in a health care assessment platform based on macromolecule-dependent data analysis, such as bioinformatics, has the potential to increase the identification of risk genes and treatment options. Though it might seem futuristic, this idea is excellent. Health professionals like clinicians and lab scientists will be able to forecast the likelihood of a disease outbreak, drug addiction, and synaptic malfunction, as well as the likelihood that a treatment will be effective, if numerous databases around the world continue to expand, increasing the likelihood of identifying a strand. The therapeutic alternative, which consists of biological and synthetic components, will be well worth the wait even though practical acceptance would take some time. In this article, we provide a brief overview of mental disorders with unclear etiologies through the visualisation of risk genes and functional vulnerability in the creation of molecular diagnostics using the Omics platform. The Omics platform's potential uses in the future illuminated the space for biomarker discovery, innovation, and the evaluation of assessment techniques for the treatment of mental health illnesses in a clinical context appears promise.
Thursday, 7 July 2022
Integration of Omics in Mental Disorders: Understanding Molecular Connectivity from Prediction to Prevention | Chapter 14 | Current Practice in Medical Science Vol. 4
Saturday, 12 March 2022
Empowering Molecular Network in the Pathogenesis of Obesity with Omics Architecture | Chapter 6 | Emerging Trends in Disease and Health Research Vol.4.
Obesity is regarded as a major public health concern, owing to the multifaceted factors involved in metabolic complications rooted in multifactorial causes (e.g., environmental toxicity or genetic abnormality), as well as the unmet landscape of the health-care system in search of therapeutic or prevention methods. Evidence that supports Omics as a strategic tool of systemic biology is being used to define the wiring of the molecular circuit in metabolic malfunctions, as well as the evaluation of metabolic modulators such as synthetic drugs, stem cell replacement, and natural secondary metabolites derived from various sources. The link between the nutritional environment and cellular/genetic processes is referred to as nutritional genomics or Nutrigenomics. Its goal is to figure out how nutrition affects a person's genes and health. Nutrigenomics strives to give a genetic understanding of how common food ingredients (i.e., nutrition) modify the expression or structure of an individual's genetic makeup, hence affecting the balance of health and sickness. Furthermore, enhancing detection capabilities from patient clinical samples and monitoring illness progression in reserve populations, who may be at a higher risk of disease susceptibility due to numerous micro- and macro-environmental variables, remains a preventative thread in public health informatics. By utilising the omics platform, which includes epigenetics, metabolomics, nutrigenomics, transcriptomics, pharmacogenomics, and genomics, molecular-based detection systems can forecast evolving disease in terms of key molecule modifications that may contribute to disease pathogenesis and reflect heredity, such as quantitative trait loci, polymorphism, and epigenetic modification. Furthermore, a customised or personalised approach to treating metabolic disease could be applied by building a person's health algorithm in conjunction with a molecular chain-based surveillance and prevention system. To encourage effective biomarker discoveries in the field of molecular therapy and early detection target molecules in obesity, early diagnostic tools as a potential strategy has inspired us in clinical validation and assessment to improve prevention/treatment outcomes for a better translation medicine process. In this short review, we aim to better understand the interaction and connectivity between risks and metabolic disorders like obesity by utilising the molecular drive platform that OMICS technologies are worthy of developing a clinical assessment with regard to diagnosing, predicting, and treating metabolic disease chains (i.e., initiation, progress, and determination) and defining causative molecule-based wiring on host defence machinery after exposure to various unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown Nutrigenomics, as a crucial strategical method to detecting genetic variation or disclosing faults of the host defence system in metabolic disorders, can be used not only to assess one's risk for obesity, but also to treat obesity through the creation of individualised diet regimens.
Author(s) Details:
S. Bartley
Department of Public Health, Division of Environmental Health Science, New
York Medical College, Valhalla NY 10595, USA.
H. H. Cho,
College of Veterinary Medicine, Gyeongsang National University, Jiju Daero 501,
Jinju-City, Gyeongsangnamdo, 660-701, Korea.
D. E. Heck,
Department of Public Health, Division of Environmental Health Science, New York
Medical College, Valhalla NY 10595, USA.
J. H. Cho,
College of Veterinary Medicine, Gyeongsang National University, Jiju Daero 501,
Jinju-City, Gyeongsangnamdo, 660-701, Korea.
H. D. Kim,
Department of Public Health, Division of Environmental Health Science, New York
Medical College, Valhalla NY 10595, USA.
Please see the link here: https://stm.bookpi.org/ETDHR-V4/article/view/6049